Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 4:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 272 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Methylphenidate Clear all
Enrolling by invitation Phase 4 Interventional

Precision Care for Major Depressive Disorder

NCT06580041
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Depressive Disorder, Major
Interventions
Pramipexole, Methylphenidate, Phenelzine, Mindfulness-based Stress Sensitivity Therapy (MBSST), Complicated Grief Treatment (CGT), Care as usual (CAU) plan
Drug · Behavioral · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 16, 2026, 4:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

An Open Label Phase I/II Study of Dopamine Transporter Receptor Occupancy With OROS and Immediate Release Methylphenidate as Measured With C-11 Altropane in Human Subjects

NCT00302367
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OROS methylphenidate hydrochloride, immediate release methylphenidate hydrochloride
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Oct 16, 2026, 4:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Testing Methylphenidate for Smoking Abstinence

NCT00549640
View directory record Official record
Conditions
Smoking
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 16, 2026, 4:17 PM EDT
Completed Phase 4 Interventional Results available

Interventions for Children With Attention and Reading Disorders

NCT01133847
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Reading Disabilities
Interventions
Methylphenidate, Intensive reading instruction, Parent Training, Mixed Salt Amphetamine, Atomoxetine, Guanfacine
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
7 Years to 12 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 16, 2026, 4:17 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder

NCT01074294
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
OPDC-34712, Placebo, Stimulant Therapy
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
35
States / cities
Little Rock, Arkansas • Beverly Hills, California • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 16, 2026, 4:17 PM EDT
Not listed Not applicable Interventional

Enhancing ADHD Driving Performance With Stimulant Medication

NCT00572026
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate Transdermal System
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 25 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 3, 2009 · Synced Oct 16, 2026, 4:17 PM EDT
Withdrawn Phase 4 Interventional

Treatment of College Students With Attention-Deficit/Hyperactivity Disorder (ADHD) Using OROS Methylphenidate

NCT00931398
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
methylphenidate HCl (Concerta), Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2012 · Synced Oct 16, 2026, 4:17 PM EDT
Terminated Phase 4 Interventional Results available

Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia.

NCT01825577
View directory record Official record
Conditions
Dementia, Accidental Falls, Apathy
Interventions
Transdermal Methylphenidate
Drug
Lead sponsor
St. Louis University
Other
Eligibility
65 Years to 95 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 16, 2026, 4:17 PM EDT
Completed Phase 4 Interventional Results available

Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta

NCT00181714
View directory record Official record
Conditions
ADHD
Interventions
methylphenidate HCl (Concerta)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 17 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2013 · Synced Oct 16, 2026, 4:17 PM EDT
Completed Phase 4 Interventional Results available

A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.

NCT03811847
View directory record Official record
Conditions
Alzheimer Dementia
Interventions
Methylphenidate Extended Release Oral Capsule, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
55 Years to 95 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 16, 2026, 4:17 PM EDT
Completed Phase 4 Interventional

A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder

NCT00181571
View directory record Official record
Conditions
ADHD
Interventions
methylphenidate HCl (Concerta), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2013 · Synced Oct 16, 2026, 4:17 PM EDT
Completed Phase 3 Interventional

Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS)

NCT00018863
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
3 Years to 5 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
6
States / cities
Irvine, California • Los Angeles, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 16, 2026, 4:17 PM EDT
Completed Phase 4 Interventional Results available

Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease

NCT00526630
View directory record Official record
Conditions
Parkinson's Disease, Gait Impairment
Interventions
Methylphenidate (MPD), Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
35 Years to 85 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 16, 2026, 4:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Understanding Sleep Problems in Children With Autism Spectrum Disorder

NCT00691080
View directory record Official record
Conditions
Sleep Problems
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
4 Years to 9 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
3
States / cities
New York, New York • Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Oct 16, 2026, 4:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study To Evaluate The Difference In iPad-Based Cognitive Video Game (Akili Interactive's Project: EVO) Performance In Amyloid-Positive Versus Amyloid-Negative Healthy Elderly Volunteers

NCT02265718
View directory record Official record
Conditions
Healthy
Interventions
Ritalin, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
70 Years to 80 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
4
States / cities
Long Beach, California • Hollywood, Florida • South Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 16, 2026, 4:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neuroimaging of Smokers With and Without Attention Deficit Hyperactivity Disorder (ADHD)

NCT01123668
View directory record Official record
Conditions
Smoking, ADHD
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 16, 2026, 4:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults

NCT00302458
View directory record Official record
Conditions
Healthy
Interventions
OROS-Methylphenidate, Immediate Release Methylphenidate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 16, 2026, 4:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Neurobiological Principles Applied to the Rehabilitation of Stroke Patients

NCT00715520
View directory record Official record
Conditions
Stroke
Interventions
Transcranial Magnetic Stimulation (TMS), Carbidopa-Levodopa, Methylphenidate, Amphetamine Sulfate, Placebo, Sham Transcranial Magnetic Stimulation (TMS), Transcranial Magnetic Stimulation (TMS) Training
Other · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 16, 2026, 4:17 PM EDT
Not listed Phase 4 Interventional

Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)

NCT00794625
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Valproate, Risperidone, Placebo, Stimulant medication, Behavioral family counseling
Drug · Behavioral
Lead sponsor
Joseph Blader
NIH
Eligibility
6 Years to 12 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Glen Oaks, New York • Stony Brook, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Oct 16, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Brain Networks and Addiction Susceptibility

NCT01924468
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Oral methylphenidate and Oral haloperidol
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 16, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Assess How Centanafadine Interacts With Stimulants in the Body

NCT07314333
View directory record Official record
Conditions
ADHD
Interventions
Centanafadine, Methylphenidate, Lisdexamfetamine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 16, 2026, 4:17 PM EDT
Recruiting Phase 4 Interventional

An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening

NCT06577779
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Methylphenidate Hydrochloride Extended Release Capsule
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 16, 2026, 4:17 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults

NCT00301639
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OROS methylphenidate hydrochloride, methylphenidate hydrochloride
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Oct 16, 2026, 4:17 PM EDT
Completed Phase 1 Interventional

Methylphenidate Treatment for Cocaine Abuse and ADHD - 1

NCT00136734
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Cocaine-Related Disorders
Interventions
Methylphenidate, placebo
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 16, 2026, 4:17 PM EDT